Radiopharm Theranostics (ASX:RAD) DeferredTaxAndRevenue: A$1.72 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics DeferredTaxAndRevenue?

Radiopharm Theranostics ASX:RAD DeferredTaxAndRevenue is A$1.72 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Radiopharm Theranostics's current deferred tax and revenue for the quarter that ended in Jun. 2025 was A$1.72 Mil.

Radiopharm Theranostics DeferredTaxAndRevenue Related Terms

Radiopharm Theranostics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics DeferredTaxAndRevenue Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
0.00 0.00 2.36 1.72

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
DeferredTaxAndRevenue Get a 7-Day Free Trial 0.00 0.00 2.36 3.16 1.72
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$1.72 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a DeferredTaxAndRevenue of A$1.72 Mil as of Jun. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Radiopharm Theranostics.
Is Radiopharm Theranostics' DeferredTaxAndRevenue too high?
Radiopharm Theranostics' current DeferredTaxAndRevenue is A$1.72 Mil.
How does Radiopharm Theranostics' DeferredTaxAndRevenue compare to VRTX and REGN?
Radiopharm Theranostics' DeferredTaxAndRevenue of A$1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Radiopharm Theranostics. Radiopharm Theranostics's current DeferredTaxAndRevenue is A$1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current DeferredTaxAndRevenue of A$1.72 Mil. The current DeferredTaxAndRevenue is A$1.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current DeferredTaxAndRevenue is A$1.72 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.